Omega-3 and polyunsaturated fat for prevention of depression and anxiety symptoms: Systematic review and meta-analysis of randomised trials

British Journal of Psychiatry

Volumn 218, Issue 3, 2021, Pages 135-142

  Deane, Katherine H O ^a   Jimoh, Oluseyi F ^b   Biswas, Priti ^a   O'Brien, Alex ^b   Hanson, Sarah ^a   Abdelhamid, Asmaa S ^b   Fox, Chris ^b   Hooper, Lee ^b  

^a UNIVERSITY OF EAST ANGLIA   (United Kingdom)

^b UNIVERSITY OF EAST ANGLIA   (United Kingdom)

Author keywords

anxiety; depression; Fatty acids omega 3; fatty acids omega 6; meta analysis

Indexed keywords

ANTIDEPRESSANT AGENT; LINOLENIC ACID; OMEGA 3 FATTY ACID; OMEGA 6 FATTY ACID;

ANXIETY DISORDER; CONTROLLED STUDY; DEPRESSION; DIET SUPPLEMENTATION; DISEASE DURATION; DISEASE SEVERITY; HUMAN; MENTAL HEALTH; META ANALYSIS; PSYCHOPHARMACOTHERAPY; RANDOMIZED CONTROLLED TRIAL (TOPIC); REMISSION; REVIEW; SYSTEMATIC REVIEW; ADULT; ANXIETY; CARDIOVASCULAR DISEASE; CAUSE OF DEATH; PREVENTION AND CONTROL; PRIMARY PREVENTION; SECONDARY PREVENTION;

ADULT; ANXIETY; CARDIOVASCULAR DISEASES; CAUSE OF DEATH; DEPRESSION; HUMANS; PRIMARY PREVENTION; RANDOMIZED CONTROLLED TRIALS AS TOPIC; SECONDARY PREVENTION;

EID: 85101513325     PISSN: 00071250     EISSN: 14721465     Source Type: Journal    
DOI: 10.1192/bjp.2019.234     Document Type: Review

References (70)

1. Papanikolaou Y, Brooks J, Reider C, Fulgoni VL. U.S. adults are not meeting recommended levels for fish and omega-3 fatty acid intake: results of an analysis using observational data from NHANES 2003-2008. Nutr J 2014; 13: 31.
2. Kyu HH, Abate D, Abate KH, Abay SM, Abbafati C, Abbasi N, et al. Global, regional, and national disability-adjusted life-years (DALYs) for 359 diseases and injuries and healthy life expectancy (HALE) for 195 countries and territories, 1990-2017: a systematic analysis for the Global Burden of Disease Study 2017. Lancet 2018; 392(10159): 1859-922.
3. Demyttenaere K, Bruffaerts R, Posada-Villa J, Gasquet I, Kovess V, Lepine JP, et al. Prevalence, severity, and unmet need for treatment of mental disorders in the World Health Organization World Mental Health Surveys. JAMA 2004; 291(21): 2581-90.
4. Kessler RC, Angermeyer M, Anthony JC, De Graaf R, Demyttenaere K, Gasquet I, et al. Lifetime prevalence and age-of-onset distributions of mental disorders in the World Health Organization's World Mental Health Survey Initiative. World Psychiatry 2007; 6(3): 168-76.
5. Wang J, Wu X, Lai W, Long E, Zhang X, Li W, et al. Prevalence of depression and depressive symptoms among outpatients: a systematic review and metaanalysis. BMJ Open 2017; 7(8): e017173.
6. Broen MPG, Narayen NE, Kuijf ML, Dissanayaka NNW, Leentjens AFG. Prevalence of anxiety in Parkinson's disease: a systematic review and meta-analysis. Mov Disord 2016; 31(8): 1125-33.
7. Matcham F, Rayner L, Steer S, Hotopf M. The prevalence of depression in rheumatoid arthritis: a systematic review and meta-analysis. Rheumatology (Oxford) 2013; 52(12): 2136-48.
8. Dyall SC. Long-chain omega-3 fatty acids and the brain: a review of the independent and shared effects of EPA, DPA and DHA. Front Aging Neurosci 2015; 7: 52.
9. Su K-P, Matsuoka Y, Pae C-U. Omega-3 polyunsaturated fatty acids in prevention of mood and anxiety disorders. Clin Psychopharmacol Neurosci 2015; 13(2): 129-37.
10. Larrieu T, Layé S. Food for mood: relevance of nutritional omega-3 fatty acids for depression and anxiety. Front Physiol 2018; 9: 1047.
11. Grosso G, Micek A, Marventano S, Castellano S, Mistretta A, Pajak A, et al. Dietary n-3 PUFA, fish consumption and depression: a systematic review and meta-analysis of observational studies. J Affect Disord 2016; 205: 269-81.
12. Thesing CS, Bot M, Milaneschi Y, Giltay EJ, Penninx BWJH. Omega-3 and omega-6 fatty acid levels in depressive and anxiety disorders. Psychoneuroendocrinology 2018; 87: 53-62.
13. Green P, Hermesh H, Monselise A, Marom S, Presburger G, Weizman A. Red cell membrane omega-3 fatty acids are decreased in nondepressed patients with social anxiety disorder. Eur Neuropsychopharmacol 2006; 16(2): 107-13.
14. Appleton KM, Sallis HM, Perry R, Ness AR, Churchill R. Omega-3 fatty acids for depression in adults. Cochrane Database Syst Rev 2015; 11: CD004692.
15. Abdelhamid AS, Brown TJ, Brainard JS, Biswas P, Thorpe GC, Moore HJ, et al. Omega-3 fatty acids for the primary and secondary prevention of cardiovascular disease. Cochrane Database Syst Rev 2018; 11: CD003177.
16. Abdelhamid AS, Martin N, Bridges C, Brainard JS, Wang X, Brown TJ, et al. Polyunsaturated fatty acids for the primary and secondary prevention of cardiovascular disease. Cochrane Database Syst Rev 2018; 11: CD012345.
17. Hooper L, Al-Khudairy L, Abdelhamid AS, Rees K, Brainard JS, Brown TJ, et al. Omega-6 fats for the primary and secondary prevention of cardiovascular disease. Cochrane Database Syst Rev 2018; 11: CD011094.
18. Abdelhamid A, Hooper L, Sivakaran R, Hayhoe RPG, Welch A, The PUFAH Group. The relationship between omega-3, omega-6 and total polyunsaturated fat and musculoskeletal health and functional status in adults: a systematic review and meta-analysis of RCTs. Calcif Tissue Int 2019; 105: 353-72.
19. Brown TJ, Brainard J, Song F, Wang X, Abdelhamid A, Hooper L. Omega-3, omega-6, and total dietary polyunsaturated fat for prevention and treatment of type 2 diabetes mellitus: systematic review and meta-analysis of randomised controlled trials. BMJ 2019; 366: l4697.
20. Brainard J, Jimoh OF, Deane K, Biswas P, Donaldson D, Maas K, et al. Omega-3, omega-6 and total polyunsaturated fat for cognition and dementia: systematic review and meta-analysis of RCTs. JAMDA, in press, 2019.
21. Hanson S, Thorpe G, Winstanley L, Abdelhamid AS, Hooper L. Omega-3, omega-6 and total dietary polyunsaturated fat on cancer incidence: systematic review and meta-analysis of randomised trials. Br J Cancer, in press, 2019.
22. Hooper L, Abdelhamid A, Brainard J, Deane KHO, Song F. Creation of a database to assess effects of omega-3, omega-6 and total polyunsaturated fats on health: database and methodology for a set of reviews. BMJ Open 2019; 9(5): e029554.
23. Thorpe G, Ajabnoor S, Ahmed Z, Abdelhamid A, Hooper L. Dietary Polyunsaturated Fat for Prevention and Treatment of Inflammatory Bowel Disease. PROSPERO, 2017 (https://www.crd.york.ac.uk/PROSPERO/display-record.php?RecordID=68704).
24. Browning LM, Walker CG, Mander AP, West AL, Madden J, Gambell JM, et al. Incorporation of eicosapentaenoic and docosahexaenoic acids into lipid pools when given as supplements providing doses equivalent to typical intakes of oily fish. Am J Clin Nutr 2012; 96(4): 748-58.
25. Higgins JPT, Altman DG, Sterne JAC, Cochrane Statistical Methods Group, Cochrane Bias Methods Group. Chapter 8: Assessing risk of bias in included studies. In Cochrane Handbook for Systematic Reviews of Interventions Version 510 [updated March 2011] (eds JPT Higgins, S Green): section 8.5. The Cochrane Collaboration, 2011.
26. McKenzie JE, Herbison GP, Deeks JJ. Impact of analysing continuous outcomes using final values, change scores and analysis of covariance on the performance of meta-analytic methods: a simulation study. Res Synth Methods 2016; 7(4): 371-86.
27. Review Manager (RevMan) Version 5.3. The Cochrane Collaboration, 2014 (https://community.cochrane.org/help/tools-and-software/revman-5/revman-5-download/installation).
28. Tajalizadekhoob Y, Sharifi F, Fakhrzadeh H, Mirarefin M, Ghaderpanahi M, Badamchizade Z, et al. The effect of low-dose omega 3 fatty acids on the treatment of mild to moderate depression in the elderly: a double-blind, randomized, placebo-controlled study. Eur Arch Psychiatry Clin Neurosci 2011; 261(8): 539-49.
29. Harbord RM, Egger M, Sterne JAC. A modified test for small-study effects in meta-analyses of controlled trials with binary endpoints. Stat Med 2006; 25 (20): 3443-57.
30. Kromhout D, Giltay EJ, Geleijnse JM. Alpha Omega Trial Group. n-3 fatty acids and cardiovascular events after myocardial infarction. N Engl J Med 2010; 363 (21): 2015-26.
31. Chew EY, Clemons TE, Agron E, Launer LJ, Grodstein F, Bernstein PS, et al. Effect of omega-3 fatty acids, lutein/zeaxanthin, or other nutrient supplementation on cognitive function: the AREDS2 randomized clinical trial. JAMA 2015; 314(8): 791-801.
32. Chiu CC, Su KP, Cheng TC, Liu HC, Chang CJ, Dewey ME, et al. The effects of omega-3 fatty acids monotherapy in Alzheimer's disease and mild cognitive impairment: a preliminary randomized double-blind placebo-controlled study. Prog Neuropsychopharmacol Biol Psychiatry 2008; 32(6): 1538-44.
33. Burr ML, Ashfield-Watt PA, Dunstan FD, Fehily AM, Breay P, Ashton T, et al. Lack of benefit of dietary advice to men with angina: results of a controlled trial. Eur J Clin Nutr 2003; 57(2): 193-200.
34. Derosa G, Cicero AF, D'Angelo A, Borghi C, Maffioli P. Effects of n-3 PUFAs on fasting plasma glucose and insulin resistance in patients with impaired fasting glucose or impaired glucose tolerance. BioFactors 2016; 42(3): 316-22.
35. Tokudome S, Kuriki K, Yokoyama Y, Sasaki M, Joh T, Kamiya T, et al. Dietary n-3/long-chain n-3 polyunsaturated fatty acids for prevention of sporadic colorectal tumors: a randomized controlled trial in polypectomized participants. Prostaglandins Leukot Essent Fatty Acids 2015; 94: 1-11.
36. Einvik G, Ekeberg O, Lavik JG, Ellingsen I, Klemsdal TO, Hjerkinn EM. The influence of long-term awareness of hyperlipidemia and of 3 years of dietary counseling on depression, anxiety, and quality of life. J Psychosom Res 2010; 68(6): 567-72.
37. Sanyal AJ, Abdelmalek MF, Suzuki A, Cummings OW, Chojkier M, Group E. No significant effects of ethyl-eicosapentanoic acid on histologic features of nonalcoholic steatohepatitis in a phase 2 trial. Gastroenterology 2014; 147(2): 377-84.
38. Danthiir V, Hosking D, Burns NR, Wilson C, Nettelbeck T, Calvaresi E, et al. Cognitive performance in older adults is inversely associated with fish consumption but not erythrocyte membrane n-3 fatty acids. J Nutr 2014; 144(3): 311-20.
39. Ferreira JJ, Rosser A, Craufurd D, Squitieri F, Mallard N, Landwehrmeyer B. Ethyl-eicosapentaenoic acid treatment in Huntington's disease: a placebocontrolled clinical trial. Mov Disord 2015; 30(10): 1426-9.
40. Hashimoto M, Kato S, Tanabe Y, Katakura M, Mamun AA, Ohno M, et al. Beneficial effects of dietary docosahexaenoic acid intervention on cognitive function and mental health of the oldest elderly in Japanese care facilities and nursing homes. Geriatr Gerontol Int 2016; 17(2): 330-7.
41. Jackson PA, Forster JS, Bell JG, Dick JR, Younger I, Kennedy DO. DHA supplementation alone or in combination with other nutrients does not modulate cerebral hemodynamics or cognitive function in healthy older adults. Nutrients 2016; 8: 86.
42. Lee SP, Dart AM, Walker KZ, O'Dea K, Chin-Dusting JP, Skilton MR. Effect of altering dietary n-6:n-3 PUFA ratio on cardiovascular risk measures in patients treated with statins: a pilot study. Br J Nutr 2012; 108(7): 1280-5.
43. Vellas B, Carrie I, Guyonnet S, Touchon J, Dantoine T, Dartigues JF, et al. MAPT (multi-domain Alzheimer's prevention trial): results at 36 months. Alzheimer's Dement 2015; 11: 331.
44. Van De Rest O, Geleijnse JM, Kok FJ, van Staveren WA, Dullemeijer C, Olderikkert MG, et al. Effect of fish oil on cognitive performance in older subjects: a randomized, controlled trial. Neurology 2008; 71(6): 430-8.
45. Yurko-Mauro K, McCarthy D, Rom D, Nelson EB, Ryan AS, Blackwell A, et al. Beneficial effects of docosahexaenoic acid on cognition in age-related cognitive decline. Alzheimer's Dement 2010; 6(6): 456-64.
46. McGorry PD, Nelson B, Markulev C, Yuen HP, Schäfer MR, Mossaheb N, et al. Effect of ω-3 polyunsaturated fatty acids in young people at ultrahigh risk for psychotic disorders: the NEURAPRO randomized clinical trial. JAMA Psychiatry 2017; 74(1): 19-27.
47. Torkildsen O, Wergeland S, Bakke S, Beiske AG, Bjerve KS, Hovdal H, et al. Omega-3 fatty acid treatment in multiple sclerosis (OFAMS study): a randomized, double-blind, placebo-controlled trial. Arch Neurol 2012; 69(8): 1044-51.
48. Pawelczyk T, Grancow-Grabka M, Kotlicka-Antczak M, Trafalska E, Pawelczyk A. A randomized controlled study of the efficacy of six-month supplementation with concentrated fish oil rich in omega-3 polyunsaturated fatty acids in first episode schizophrenia. J Psychiatr Res 2016; 73: 34-44.
49. Freund-Levi Y, Basun H, Cederholm T, Faxen-Irving G, Garlind A, Grut M, et al. Omega-3 supplementation in mild to moderate Alzheimer's disease: effects on neuropsychiatric symptoms. Int J Geriatr Psychiatry 2008; 23(2): 161-9.
50. Rauch B, Schiele R, Schneider S, Diller F, Victor N, Gohlke H, et al. OMEGA, a randomized, placebo-controlled trial to test the effect of highly purified omega-3 fatty acids on top of modern guideline-adjusted therapy after myocardial infarction. Circulation 2010; 122(21): 2152-9.
51. Dangour AD, Allen E, Elbourne D, Fasey N, Fletcher AE, Hardy P, et al. Effect of 2-y n-3 long-chain polyunsaturated fatty acid supplementation on cognitive function in older people: a randomized, double-blind, controlled trial. Am J Clin Nutr 2010; 91(6): 1725-32.
52. Palma C. Omega 3 fatty acids supplementation in Schizophrenia. Eur Arch Psychiatry Clin Neurosci 2015; 265(Suppl 1): S122-S.
53. Pomponi M, Loria G, Salvati S, Di Biase A, Conte G, Villella C, et al. DHA effects in Parkinson disease depression. Basal Ganglia 2014; 4(2): 61-6.
54. Pratt CM, Reiffel JA, Ellenbogen KA, Naccarelli GV, Kowey PR. Efficacy and safety of prescription omega-3-acid ethyl esters for the prevention of recurrent symptomatic atrial fibrillation: a prospective study. Am Heart J 2009; 158(2): 163-9.
55. Sinn N, Milte CM, Street SJ, Buckley JD, Coates AM, Petkov J, et al. Effects of n-3 fatty acids, EPA v. DHA, on depressive symptoms, quality of life, memory and executive function in older adults with mild cognitive impairment: a 6-month randomised controlled trial. Br J Nutr2012; 107(11): 1682-93.
56. Galan P, Kesse-Guyot E, Czernichow S, Briancon S, Blacher J, Hercberg S, et al. Effects of B vitamins and omega 3 fatty acids on cardiovascular diseases: a randomised placebo controlled trial. BMJ 2010; 341: c6273.
57. Tuttle KR, Shuler LA, Packard DP, Milton JE, Daratha KB, Bibus DM, et al. Comparison of low-fat versus Mediterranean-style dietary intervention after first myocardial infarction (from The Heart Institute of Spokane Diet Intervention and Evaluation Trial). Am J Cardiol 2008; 101(11): 1523-30.
58. Huntington Study Group. Randomized controlled trial of ethyl-eicosapentaenoic acid in Huntington disease: the TREND-HD study. Arch Neurol 2008; 65(12): 1582-9.
59. ASCEND Study Collaborative Group. Effects of n-3 fatty acid supplements in diabetes mellitus. N Engl J Med 2018; 379(16): 1540-50.
60. Andrieu S, Guyonnet S, Coley N, Cantet C, Bonnefoy M, Bordes S, et al. Effect of long-term omega 3 polyunsaturated fatty acid supplementation with or without multidomain intervention on cognitive function in elderly adults with memory complaints (MAPT): a randomised, placebo-controlled trial. Lancet Neurol 2017; 16(5): 377-89.
61. Van De Rest O, Geleijnse JM, Kok FJ, van Staveren WA, Hoefnagels WH, Beekman AT, et al. Effect of fish-oil supplementation on mental well-being in older subjects: a randomized, double-blind, placebo-controlled trial. Am J Clin Nutr 2008; 88(3): 706-13.
62. Estruch R, Ros E, Salas-Salvadó J, Covas M, Corella D, Arós F, et al. Retraction and republication: primary prevention of cardiovascular disease with a Mediterranean diet. N Engl J Med 2013;368:1279-90. N Engl J Med 2018; 378: 2441-2.
63. Bot M, Brouwer IA, Roca M, Kohls E, Penninx BWJH, Watkins E, et al. Effect of multinutrient supplementation and food-related behavioral activation therapy on prevention of major depressive disorder among overweight or obese adults with subsyndromal depressive symptoms: the MooDFOOD randomized clinical trial. JAMA 2019; 321(9): 858-68.
64. Su K-P, Tseng P-T, Lin P-Y, Okubo R, Chen T-Y, Chen Y-W, et al. Association of use of omega-3 polyunsaturated fatty acids with changes in severity of anxiety symptoms: a systematic review and meta-analysis. JAMA Netw Open 2018; 1(5): e182327.
65. Mocking RJ, Harmsen I, Assies J, KoeterMW, Ruhe HG, Schene AH.Meta-analysis and meta-regression of omega-3 polyunsaturated fatty acid supplementation for major depressive disorder. Transl Psychiatry 2016; 6: e756.
66. Bai Z-G, Bo A, Wu S-J, Gai Q-Y, Chi I. Omega-3 polyunsaturated fatty acids and reduction of depressive symptoms in older adults: a systematic review and meta-analysis. J Affect Disord 2018; 241: 241-8.
67. Hallahan B, Ryan T, Hibbeln JR, Murray IT, Glynn S, Ramsden CE, et al. Efficacy of omega-3 highly unsaturated fatty acids in the treatment of depression. Br J Psychiatry 2018; 209(3): 192-201.
68. Yang JR, Han D, Qiao ZX, Tian X, Qi D, Qiu XH. Combined application of eicosapentaenoic acid and docosahexaenoic acid on depression in women: a meta-analysis of double-blind randomized controlled trials. Neuropsychiatr 2015; 11: 2055-61.
69. Geleijnse J, Giltay E, Kromhout D. Effects of n-3 fatty acids on cognitive decline: a randomized double-blind, placebo-controlled trial in stable myocardial infarction patients. Alzheimer's Dement 2011; 1: S512.
70. Burr ML, Ashfield-Watt PA, Dunstan FD, Fehily AM, Breay P, Ashton T, et al. Lack of benefit of dietary advice to men with angina: results of a controlled trial. Eur J Clin Nutr 2003; 57(2): 193-200.